Intestinal graft-versus-host disease (GVHD) produces clinical manifestations and histological changes resembling those of ulcerative colitis and has been treated with drugs which are used for ulcerative colitis. These two conditions also resemble each other with respect to changes of cytokines. Accordingly, we investigated whether the level of leukotriene B4, a risk factor for ulcerative colitis, was also a risk factor or prognostic indicator for intestinal GVHD. The pre-conditioning leukotoriene B4 level was significantly related to the grade of intestinal GVHD in 42 patients (P Ͻ 0.01). Compared with patients who did not develop severe intestinal GVHD after bone marrow transplantation, those who did had significantly higher interleukin-2 and interferon-␥ levels during the aplastic phase (P Ͻ0.01), followed by higher tumor necrosis factor-␣ levels during the recovery phase (P Ͻ 0.0001), with significant elevation of tumor necrosis factor-␣ and interferon-␥ occurring in association with exacerbations of intestinal GVHD (P Ͻ 0.001). These findings suggest a similarity between the pathogenesis of ulcerative colitis and intestinal GVHD and raise the possibility that leukotriene B4 may be a useful prognostic indicator for intestinal GVHD. Bone Marrow Transplantation (2000) 26, 1313-1316. 
Graft-versus-host disease (GVHD) is a very important complication of bone marrow transplantation (BMT). 1 Among the various types of GVHD, intestinal GVHD is common and has a propensity for becoming serious. It is therefore one of the most important factors upon which the outcome of BMT depends. We have previously reported that intestinal GVHD is very similar to ulcerative colitis (UC) with regard to changes in cytokines, as well as with respect to the pathological findings and drugs used for treatment (manuscript submitted). The present study was performed to determine whether the pre-conditioning level of leukotriene B4 (LTB4), one of the risk factors for UC, could be a risk factor for intestinal GVHD after BMT or a predictor of its severity.
Materials and methods

Subjects
The subjects were 42 consecutive patients who underwent allogeneic BMT at our institution from July 1996 to July 1999. Table 1 shows the age, sex, underlying disease, disease stage, donor type, HLA type, conditioning regimen, and GVHD prophylaxis of these patients.
Conditioning regimen and GVHD prophylaxis
The basic conditioning regimen was busulfan (Bu), cyclophosphamide (CY), and total body irradiation (TBI) (Bu at a dose of 4 mg/kg/day ϫ 2 days, CY at 30 mg/kg/day ϫ 2 days, and TBI at 3 Gy ϫ 4) or Bu and CY (Bu at 4 mg/kg day ϫ 4 days and CY at 60 mg/kg/day ϫ 2 days). For GVHD prophylaxis, the basic treatment was cyclosporin A(CsA) plus methotrexate (MTX) plus methylprednisolone (mPSL) 2 or CsA plus MTX. CsA was infused from day Ϫ1 for 24 h, and was kept at a target blood level of 400 to 600 ng/ml until marrow engraftment, after which the dose was varied depending on the symptoms of GVHD. If GVHD became worse, the doses of CsA and mPSL were increased or CsA was replaced with FK506.
Diagnosis of acute intestinal GVHD
Acute intestinal GVHD was classified according to the diagnostic criteria of the 1994 Consensus conference on acute GVHD grading, 3 and the highest grade until day 100 after transplantation was determined. Because the diagnosis and classification by grade were based mainly on clinical manifestations, an histological diagnosis was not made in all cases.
Assay of leukotriene B4 and cytokines
The LTB4 level was investigated before conditioning. The levels of tumor necrosis factor (TNF)-␣, interferon (IFN)- ALL ϭ acute lymphoblastic leukemia; AML ϭ acute myelogenous leukemia; CML ϭ chronic myelogenous leukemia; MDS ϭ myelodysplastic syndrome; SAA ϭ severe aplastic anemia; ML ϭ mixed leukemia; LBL ϭ lymphoblastic lymphoma; CR1/2 ϭ complete remission 1st/2nd; NR ϭ No remission; CP ϭ chronic phase; AP ϭ accelerated phase; R ϭ related; UR ϭ unrelated; BU ϭ busulphan; CY ϭ cyclophosphamide; TBI ϭ total body irradiation; TLI ϭ total lymph node irradiation; CsA ϭ cyclosporin A; MTX ϭ methotrexate; mPSL ϭ methylprednisolone.
␥, interleukin (IL)-1␤, and IL-2 were investigated on six occasions: (1) before conditioning, (2) day 0 of BMT (before bone marrow infusion), (3) during the aplastic phase after BMT, (4) during the rapid WBC recovery phase, (5) at the time of WBC stabilization after discontinuation of granulocyte colony-stimulating factor therapy, and (6) at the time of maximum symptoms in nine patients with severe colonic GVHD and at around the same time after BMT in 33 patients without it. G-CSF (lenograstim (5 g/kg), bilgrastim (5 g/kg), or natrograstim (8 g/kg)) was administered to all patients from day 5 until the WBC exceeded 10 ϫ 10 9 /1. Blood samples were collected into tubes containing 3.8% citric acid at a ratio of 1:9. After separation by centrifugation at 1500 r.p.m. for 10 min at 4°C, plasma was stored at Ϫ80°C. All parameters were measured in duplicate at each specified time using an ELISA kit for LTB4 from Amersham International (Amersham, UK) and kits from Endogen (Woburn, MA, USA) for the assay of cytokines. Mean values were determined on each occasion.
Statistical analysis
Statistical analysis was done using Student's t-test, and P Ͻ 0.05 was considered to indicate a significant difference.
Results
Among the 42 patients, nine developed severe acute colonic GVHD (grade III or IV), eight had grade II disease, eight had grade I disease, and 17 had no GVHD. Clinical characteristics were compared between the nine patients with severe acute colonic GVHD and the 33 patients without it. There were no significant differences in age, sex, underlying disease, disease stage, donor type, HLA match, conditioning regimen, and GVHD prophylaxis ( Table 1 ). There was no significant difference between the two groups in either incidence or severity of GVHD involving both skin and colon. The mean Ϯ s.d. (range) of the LTB4 level before conditioning was 61.2 Ϯ 41.6 (18-140) and 6.5 Ϯ 5.3 (0-17), respectively in patients with severe colonic GVHD and without it. Patients with severe colonic GVHD showed significant elevations of the LTB4 level before conditioning when compared to the patients without it (P Ͻ 0.01; t-test) (Figure 1 ). The changes in various cytokines were studied from before conditioning until the time of maximum symptoms of colonic GVHD, and these para- (a) IFN-␥: patients with severe colonic GVHD showed a significant increase of IFN-␥ during the aplastic phase and at the time of maximum symptoms (P Ͻ 0.01 and P Ͻ 0.001) (normal range, 0-2.6 pg/ml). (b) IL-2: patients with severe colonic GVHD showed a significant increase of IL-2 during the aplastic phase (P Ͻ 0.01) (normal range 0-6.5 pg/ml).
(c) TNF-␣: patients with severe colonic GVHD showed a significant increase of TNF-␣ during the recovery phase and at the time of maximum symptoms (P Ͻ 0.0001 and P Ͻ 0.01) (normal range, 0-5 pg/ml).
Bone Marrow Transplantation meters were compared between patients with and without colonic GVHD (patients without GVHD were studied around the same time as patients with it). The patients with severe acute colonic GVHD showed a significant increase of IFN-␥ and IL-2 during the aplastic phase after BMT (P Ͻ0.01; t-test) (Figure 2a and b) , as well as significant increase in TNF-␣ during WBC recovery (P Ͻ0.0001; ttest) (Figure 2c) , and of IFN-␥ and TNF-␣ at the time of maximum symptoms of colonic GVHD (P Ͻ 0.001; t-test) (Figure 2a and c) . There was no significant difference of IL-1 ␤ between patients with and without severe colonic GVHD (data not shown).
Discussion
The present study suggested that the pre-conditioning level of LTB4, a risk factor for UC, is closely related to the severity of intestinal GVHD, a complication of BMT. LTB4 is a metabolite of arachidonic acid, which is involved in the migration and adhesion of leukocytes. It also induces the liberation of lysosomal enzymes, activation of natural killer (NK) cells, and the production of TNF-␣, IL-2, and IFN-␥. [4] [5] [6] In short, it is an inflammatory mediator with potent physiological activity. It has been suggested that the development of UC is strongly dependent on the inflammatory effects of LTB4. 7, 8 In the pathogenesis of GVHD, IL-2 and IFN-␥ are induced by LTB4 and stimulate monocytes, accelerating the release of TNF-␣ and IL-1 from these cells. [4] [5] [6] In patients who have undergone BMT, the TNF-␣ and IL-1 thus produced are reported to aggravate GVHD. 9 It has also been reported that activation of NK cells results in aggravation of GVHD. 10 It seems possible that all these processes might combine to cause progression of GVHD. The present study demonstrated a close association between pre-conditioning elevation of LTB4 and the development of severe intestinal GVHD after BMT. There was significant elevation of IL-2 and IFN-␥ levels during the aplastic phase after BMT, as well as significant elevation of the TNF-␣ level during the recovery phase when the donor marrow had engrafted and leukocytes were rapidly increasing, and elevation of TNF-␣ and IFN-␥ in association with aggravation of intestinal GVHD. These results suggest that the mechanism we have proposed for induction of intestinal GVHD by LTB4 is essentially correct. The data presented above also suggest that UC and intestinal GVHD resemble each other with respect to pathogenesis. It is therefore likely that LTB4 is not only a risk factor for UC but also for intestinal GVHD, and may be a useful predictor of intestinal GVHD.
